SpiN-Tec——基于T细胞的RBD-核衣壳嵌合新冠疫苗的安全性与免疫原性
这是一项I期临床试验,36名18-54岁既往接种两剂CoronaVac™及一剂Comirnaty™二价BA.4/BA.5加强针的健康成人随机接种SpiN-Tec(20 μg、60 μg或100 μg)或CoviShield™。SpiN-Tec安全性良好,反应原性与CoviShield相当;抗N和SpiN的IgG呈剂量依赖性升高,第28天达峰、第180天下降;针对Wuhan原始株和BA1.88株的中和抗体水平与CoviShield无差异;IFN-γ反应持续至第270天,以CD4+效应记忆T细胞为主。
要点
- SpiN-Tec安全性良好,反应原性与CoviShield™相当。
- 抗N和SpiN的IgG呈剂量依赖性升高,第28天达峰、第180天下降。
- SpiN-Tec诱导的IFN-γ反应持续至第270天,以CD4+效应记忆T细胞为主。
核心结论
- SpiN-Tec安全性良好且具有免疫原性,结果提示其有潜力作为可行的COVID-19加强疫苗。
研究设计与样本
- I期临床试验,评价SpiN-Tec的安全性和反应原性。
- 36名18-54岁健康成人,既往接种两剂CoronaVac™(Sinovac)及一剂Comirnaty™二价BA.4/BA.5(Pfizer-BioNTech)加强针。
- 随机接种SpiN-Tec(20 μg、60 μg或100 μg)或CoviShield™(AstraZeneca)。
主要发现
- SpiN-Tec安全性良好,反应原性与CoviShield相当。
- 抗N和SpiN的IgG呈剂量依赖性升高,第28天达峰、第180天下降。
- 针对Wuhan原始株和BA1.88株的中和抗体水平在SpiN-Tec与CoviShield之间无差异。
- SpiN-Tec诱导强劲的IFN-γ产生至第270天,尤其由CD4+效应记忆T细胞产生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The SpiN-Tec MCTI UFMG is a chimeric recombinant protein (SpiN) containing the RBD region from the Spike protein (S) fused with the Nucleocapsid protein (N), adjuvanted with a squalene-based emulsion (CTVad1), which was developed as booster COVID-19 vaccine. This is a phase I clinical trial to evaluate safety and reactogenicity. Thirty-six healthy adults aged 18-54, previously vaccinated with two doses of CoronaVac™ (Sinovac) and a booster with the Comirnaty™ Bivalent BA.4/BA.5 (Pfizer-BioNTech), were randomized to receive either SpiN-Tec (20 μg, 60 μg, or 100 μg) or CoviShield™(AstraZeneca). SpiN-Tec was safe and showed a reactogenic profile comparable to CoviShield. Immunogenicity results showed a dose-dependent increase in IgG levels against N and SpiN, peaking at day 28 post-vaccination and declining by day 180. Neutralizing antibody levels against both the Wuhan ancestral and BA1.88 strains showed similar curves presenting no differences between SpiN-Tec and CoviShield. Importantly, SpiN-Tec induced robust IFN-γ production up to 270 days, particularly by CD4+ effector memory T cells, indicating a durable immune response memory. These results indicate the potential of SpiN-Tec as a viable COVID-19 booster vaccine.
引用
- Almeida GG, Pinto JA, Pinto PM, et al. Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19. Vaccine. 2025. PMID: 40974737. doi:10.1016/j.vaccine.2025.127756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。